TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32278771
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal 0.5 mg ranibizumab
Study: 32278771
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal 0.5 mg ranibizumab plus TRP
Study: 32278771
Drug: 3 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP
Study: 32769639
Drug: Interpersonal therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal therapy-based intervention (n=129)
Study: 37866373
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 7 days
Study: 32122863
Drug: Staging acupuncture
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staging acupuncture treatment after stroke
Study: 32596297
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (AIT) for 3 years
Study: 32245197
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (0.33 g·kg−1·d−1 protein)
Study: 32245197
Drug: Control (isonitrogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isonitrogenous control, 0.33 g·kg−1·d−1 protein)
Study: 33285602
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (1.4 mg elemental Zn/kg/d orally for 10 days)
Study: 32089329
Drug: Triple fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple fixed combination (TFC) of bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% ophthalmic solution
Study: 32089329
Drug: Dual fixed
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual fixed combination (DFC) of brimonidine 0.2%/timolol 0.5%
Study: 34512959
Drug: Niclosamide (NCS)
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide (NCS) as add-on therapy to standard of care
Study: 34512959
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy only (Control)
Study: 33421836
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide gas (N2O) administration during childbirth
Study: 33421836
Drug: Morphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administration during childbirth
Study: 33421836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both drugs with severe pain during labor
Study: 33010242
Drug: Tetravalent vaccine
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent vaccine (Ad26.Mos4.HIV)
Study: 35665918
Drug: NRTIs included
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NRTIs included in the treatment regimen
Study: 35665918
Drug: NRTIs omitted
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs omitted from the treatment regimen
Study: 33931178
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with a central action mechanism
Study: 33931178
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with a peripheral action mechanism
Study: 33931178
Drug: Dopamine antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine antagonists (specific drug type not mentioned)
Study: 35854251
Drug: Simultaneous PTSD
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous PTSD treatment
Study: 35854251
Drug: Sequential PTSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential PTSD treatment
Study: 33609066
Drug: Hypokalaemia (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypokalaemia (serum potassium <4 mmol/L)
Study: 33609066
Drug: Hyperkalaemia (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperkalaemia (serum potassium >5 mmol/L)
Study: 33609066
Drug: Normokalaemia (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normokalaemia (serum potassium 4–5 mmol/L)
Study: 34726661
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (ET) for 12 weeks
Study: 32450367
Drug: Intensive Behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Behavioral Therapy (IBT) alone
Study: 32450367
Drug: Intensive Behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Behavioral Therapy (IBT) with liraglutide 3.0 mg/d
Study: 32450367
Drug: Intensive Behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Behavioral Therapy (IBT) with liraglutide and a 12-week meal replacement diet (Multi-component)
Study: 32450367
Drug: Self-monitoring and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring and medication adherence
Study: 35947347
Drug: Triptorelin pamoate
Normalized name: Triptorelin Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks)
Study: 35947347
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks)
Study: 33298201
Drug: Lutein 20
Normalized name: lutein 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 20 mg/d along with a low-calorie diet (LCD) for 10 weeks
Study: 33785016
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg/day for one week before surgery and 60 mg/day for six weeks after surgery)
Study: 32693847
Drug: Enzymes (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymes (300 mg/kg)
Study: 32693847
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis DSM 29784 and Enzymes (1×10^9 cfu/kg and 300 mg/kg)
Study: 32693847
Drug: Enramycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enramycin (250 mg/kg)
Study: 38153624
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Study: 36646196
Drug: Rivaroxaban 5
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg twice daily alone
Study: 630982953
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg alone
Study: 32649352
Drug: Rivaroxaban and
Normalized name: rivaroxaban and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban and aspirin
Study: 35284698
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine plus ibuprofen (5 mg morphine with 800 mg ibuprofen)
Study: 35284698
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine plus ketorolac (5 mg morphine with 30 mg ketorolac)
Study: 35284698
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine alone (5 mg morphine)
Study: 32611242
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester-enriched spread (3.0 g plant stanols/d)
Study: 33128847
Drug: Generic pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic pantoprazole sodium enteric-coated tablets
Study: 33128847
Drug: Branded pantoprazole
Normalized name: Protium brand of pantoprazole sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded pantoprazole sodium enteric-coated tablets
Study: 33128847
Drug: Generic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic and branded pantoprazole sodium enteric-coated tablets
Study: 32370731
Drug: Oral 600mg
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 600mg ALA twice daily for 6 months
Study: 36890541
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) administration (1000 mg before skin incision and 6 hours after)
Study: 36890541
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without TXA administration)
Study: 36890541
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) administration
Study: 34936382
Drug: All subjects
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects receiving antibiotics
Study: 32217888
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (electro or sham)
Study: 32217888
Drug: Pharmacological hot
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological hot flash treatment (gabapentin or placebo)
Study: 34432899
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (2.2 mg on days 1 and 2; 13.2 mg on days 3 and 4)
Study: 34432899
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg twice on day 1, then 3 doses of 200 mg every 12 hours)
Study: 33181558
Drug: Closed-loop BIS-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop BIS-guided propofol and remifentanil titration
Study: 33181558
Drug: Manual BIS-guided
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual BIS-guided propofol and remifentanil titration
Study: 34953469
Drug: RA1 mouth
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA1 mouth rinse solution (0.8% proanthocyanidin-enriched extract from Rumex acetosa)
Study: 32446304
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride gargle (15 mL of 0.15% solution)
Study: 32053298
Drug: Reduced-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose regimen of oral glucocorticoids
Study: 32053298
Drug: Standard-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose regimen of oral glucocorticoids
Study: 32741789
Drug: Mismatch (Mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mismatch (Mg) group using the Te.M.P.O. application
Study: 34038198
Drug: 0.75% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% isobaric ropivacaine plus 5 µg sufentanil intrathecally (Group RS)
Study: 32062566
Drug: Real treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real treatment (rTMS)
Study: 35652434
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily applications of 1 h each
Study: 32980290
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid (180 mg once daily for 12 to 52 weeks)
Study: 32980290
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 12 to 52 weeks)
Study: 33155505
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet rich fibrin mixed with antibiotics (Colistin, Ciprofloxacin‐Colistin combination, Tobramycin)
Study: 33155505
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet rich fibrin mixed with antibiotics
Study: 32675314
Drug: Nasal Continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Continuous Positive Airway Pressure (nCPAP) administered in tertiary centers for term babies for <24 hours
Study: 34139357
Drug: Perianal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perianal injection with bulking agents (INJ)
Study: 35683992
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day RMD
Study: 35683992
Drug: 25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/day RMD
Study: 34750035
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus Ipilimumab (NIVO+IPI) every 3 weeks for four doses followed by Nivolumab monotherapy
Study: 35500098
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin (high-dose group)
Study: 35500098
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin (low-dose group)
Study: 35635580
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (endocrine therapy + chemotherapy)
Study: 33831632
Drug: Incentives for
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Incentives for medication adherence
Study: 34143714
Drug: Experiential/traditional music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential/traditional music therapy (MG group)
Study: 34143714
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with experiential/traditional music and acupuncture (AP/MG group)
Study: 33467421
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) - 30 inspiratory efforts twice daily, 5 days a week, at 50%, 60%, 70%, and 80% of maximum inspiratory pressure (MIP) for 4 weeks
Study: 33545749
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous infusion (control)
Study: 32665179
Drug: Preoperative ultrasound-guided
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative ultrasound-guided TTMPB with 20 mL of 0.25% bupivacaine
Study: 34255199
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + sterile saline solution (SSL)
Study: 34255199
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + 2% chlorhexidine gel (CHX gel)
Study: 36669426
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant radiation therapy (RT) 60Gy/30 fractions over 6 weeks
Study: 36669426
Drug: Accelerated radiation
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiation therapy (6 d a week)
Study: 36669426
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-risk features (T3-T4 primary tumours with N2-N3 nodes along with ECE)
Study: 34190016
Drug: Bedtime hypertension
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime hypertension chronotherapy (ingestion of BP-lowering medications at bedtime)
Study: 34190016
Drug: Upon-waking/morning hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon-waking/morning hypertension treatment-time scheme
Study: 34039478
Drug: Aminoglycosides (amikacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides (amikacin and gentamicin) administered during CRRT.
Study: 34039478
Drug: Inappropriate reinjection
Normalized name: vaccinia virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate reinjection threshold for gentamicin (>2 mg/L) and amikacin (>5 mg/L).
Study: 32196898
Drug: Outpatient oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient oral treatment (cefixime)
Study: 32196898
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (cefepime)
Study: 32803560
Drug: Medication dispensing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication dispensing errors
Study: 32803560
Drug: Prescription related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription related errors
Study: 32803560
Drug: Wrong drug
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrong drug errors
Study: 33173165
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to standard adjuvant chemotherapy (FOFOX or XELOX)
Study: 33173165
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy (FOFOX or XELOX) without bevacizumab
Study: 32958269
Drug: Water-only fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-only fasting for 24 hours before and 24 hours after each chemotherapy cycle
Study: 616063474
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (BB)
Study: 616063474
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (BB) after enrolment
Study: 616063474
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (BB) in TNBC
Study: 616063474
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (BB) in RAM arm
Study: 616063474
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (BB) after enrolment in RAM arm
Study: 616063474
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (BB) and treatment-emergent hypertension
Study: 616063474
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (BB) and treatment arm interaction
Study: 34226218
Drug: Microablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microablative fractional radiofrequency (MAFRF) treatment
Study: 33955835
Drug: VR cognitive
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR cognitive training (multidomain and neuropsychologist-assisted) in a fully immersive VR environment, twice a week for 1 month
Study: 33955835
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual therapy such as pharmacotherapy)
Study: 32602000
Drug: Combination method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination method using CEUS and blue dye (BD)
Study: 34159732
Drug: Rectus sheath
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectus sheath block (RSB) with 10 mL of 0.375% ropivacaine
Study: 34159732
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (LA) with subcutaneous and fascial injection of 10 mL of 0.75% ropivacaine
Study: 32731841
Drug: Colon capsule
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon capsule endoscopy (CCE)
Study: 33152308
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy after chemoradiotherapy
Study: 32179241
Drug: Anthocyanins 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins 320 mg/day
Study: 32179241
Drug: Anthocyanins 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins 40 mg/day
Study: 32179241
Drug: Anthocyanins 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins 80 mg/day
Study: 32179241
Drug: Anthocyanins (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (all doses)
Study: 32041913
Drug: Ciplukan extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciplukan extract 3 x 250 mg/day for 12 weeks
Study: 34911721
Drug: Experimental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapy (specifics not provided)
Study: 36181377
Drug: Sugammadex (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (8 mg∙kg−1)
Study: 36181377
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 mg∙kg−1 and 4 mg∙kg−1)
Study: 36181377
Drug: Neostigmine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.03 mg∙kg−1)
Study: 32538746
Drug: TACE in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE in combination with lobaplatin
Study: 32538746
Drug: TACE in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE in combination with cisplatin (Control group)
Study: 33057999
Drug: Physician-directed replacement
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-directed replacement (any choice of steroid, dose or route)
Study: 33057999
Drug: Fixed-dose dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed-dose dexamethasone 8 mg oral before starting docetaxel